It’s official. OCTANe has launched the sequel fund to its first Visionary Ventures LP fund. This one, known as Visionary Ventures II LP, will be a more diversified fund with a primary focus on ophthalmology. Its secondary focus will be on
With a successful ophthalmology fund under its belt and a sequel fund on the way, OCTANe is now looking to replicate the success that this specialized focus has achieved, this time in the fintech and data analytic realms. Bill Carpou, CEO
*NEWS: Novartis Confirmation of Alcon Spinoff Happens to Coincide with OCTANe’s Ophthalmology Technology Summit. Alcon Says Will Keep Manufacturing and BD&L in OC.
OCTANe’s annual 2018 Ophthalmology Technology Summit on June 29 coincided with the national news that Novartis will definitely spin off Alcon – with a presence in Lake Forest - to shareholders and buy back up to $5 billion in stock,
An OC-based fund dedicated to ophthalmology ventures has been a success for investors and a sequel fund will be launched. That’s the news relayed Friday by Visionary Ventures Fund LP Managing Partner Jeffry Weinhuff. He announced the news at OCTANe’s annual
Entrepreneur innovators have catalyzed the ophthalmology industry from the get-go, starting with one of the first - Gavin Herbert, who created Allergan more than 50 years ago. Allergan evolved into a multinational pharma company that produces branded drugs and does
*UPDATE From OCTANe’s Ophthalmology Technology Summit: Allergan Acts Like a Startup in Terms of Innovation and Disruption
Innovation within the ophthalmology and optometry industries in general - and Allergan specifically - continues to be crucial, CEO Brent Saunders told attendees at OCTANe’s annual Ophthalmology Technology Summit on June 29. OCTANe is a life sciences and tech accelerator